These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

Last week’s full-year results from GlaxoSmithKline (GSK) do not answer every concern the sceptics may have regarding current ...

The app attracted a lot of attention during the pandemic as a potentially way to differentiate COVID-19 from other respiratory infections, but Merck says ... first-in-class drug for chronic ...

SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered ... on those where immunotherapy with drugs like Keytruda is known to have an ...

Welcome to McKesson's third-quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the call over to Rachel Rodriguez, ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...